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Background: Pericardial effusion is a commonly reported complication of infection with the human immunodeficiency virus (HIV). In the past, 
it has been estimated to be present in approximately 11% of patients with HIV, and it is often associated with increased morbidity and mortality. 
However, the prevalence of pericardial effusion in HIV patients since the advent of highly active antiretroviral therapy (HAART) has not been well 
defined.
Methods: Patients with documented HIV infection who underwent echocardiography between January 1, 2000 and December 31st, 2008 were 
identified, and clinical information from the institution’s electronic medical record was obtained. Those with coexisting disorders known to be 
associated with pericardial effusions were excluded. Demographic data, including antiretroviral treatment, CD4 count and HIV viral load within 3 
months of echocardiogram were obtained. Echocardiograms were reviewed to confirm the presence and size of any identified pericardial effusion.
Results: One hundred-thirteen patients were eligible for inclusion in the study. Sixty-six patients (58.4%) were actively receiving HAART at the 
time of echocardiography. Pericardial effusion was found in 1.5% (1/66) of patients receiving HAART, compared to 17.0% (8/ 47) of patients not 
receiving active treatment (p < 0.01). HAART therapy resulted in higher median CD4 counts (305 vs. 186, p = 0.026) and lower median HIV viral 
load (0 vs. 75000, p < 0.0001), however these values did not independently correlate with the presence of pericardial effusion.
Conclusions: The use of HAART for patents with HIV is associated with a low incidence of pericardial effusion, which is significantly reduced when 
compared directly to contemporary patients not receiving similar treatment. These findings also demonstrate a substantial decline in the prevalence 
of pericardial effusion in HIV patients compared to previously reported rates prior to the era of HAART.
